“茂华药液Ⅰ号”配合放疗治疗食管癌的临床研究  

Clinical research on esophageal carcinoma treated with radiotherapy combined with Maohua Medical liquid Ⅰ

作　　者：张光明[1] 王传茂[2] 杨会华[2] 龙会兰 于福江[2] 许太玉[2] 

机构地区：[1]泰安市肿瘤防治院,山东泰安271000 [2]泰安市中医二院,山东泰安271000

出　　处：《泰山医学院学报》2005年第3期214-217,共4页Journal of Taishan Medical College

基　　金：山东省中医药管理局基金资助(2001-103)

摘　　要：目的提高食管癌放疗的疗效,防治放疗并发症,提高患者的生活质量.方法精选黄芪、杜仲、川断、炙首乌等20多味中药,经过特定工艺制成'茂华药液Ⅰ号'.选择病理确诊的食管癌180例,随机分为实验组(放疗加'茂华药液'口服)、对照组(单纯放疗)和西药组(放疗同时服用鲨肝醇、利血升、VitB4),进行前瞻性治疗、观察.结果放疗结束后1月KPS评分:实验组、对照组和西药组分别平均增长17.5、11和12.3分,试验组与对照组、西药组比较(下同),P均＜0.05;体重增加≥1 kg者:实验组47.5%,对照组25.4%,西药组30%,P均＜0.05;病灶消退情况:实验组优于对照组和西药组;1年肿瘤局部控制率:实验组62.3%,对照组44.1%,西药组41.7%,P均＜0.05;1、2年生存率:实验组72.1%、59%,对照组54.2%、40.7%,西药组51.7%、41.7%,P均＜0.05;副反应:1～2级放射性食管炎的发生率:实验组41%,对照组69.5%,西药组63.3%,P＜0.01、P＜0.05;血白细胞＜4×109/L者:实验组24.6%,对照组52.5%,西药组48.3%,P均＜0.01;实验组肝肾功能治疗前后无统计学差异(P＞0.05).结论'茂华药液Ⅰ号'药理作用明显,配合放疗治疗食管癌能提高肿瘤的局部控制率,提高了患者的1、2年生存率,明显地减轻了放射性食管炎、骨髓抑制等放疗并发症.Objective： To improve curative effects and decrease complications and increase living quality of esophageal carcinoma patients. Methods： The Chinese herbal medicines Astragalus mernbranaceus, Eucommia ulmoides Oliv, Polygonum multiflorum etc with more than 20 flavors were careffuly selected and made into medical liquid through particular craft named as maohua medical liquid Ⅰ. 180 cases esophageal carcinoma patients were divided into 3 groups： experiment group, contrast group and westen medicine group. The experiment group was treated with radiotherapy combined with maohua medical liquid Ⅰ; The contrast group was treated with radiotherapy alone; The Westen medicine group was treated with radiotherapy combined with some westen medicine, such as Victamine B4, etc. Results： （1） one months later after the treatment, the KPS score of the experiment group patients increased by an average of 17.5 and the contrast group 11 （P 〈 0.01）. （2） The percentage of weight increased of more than 1 kilogramme in the experiment group was 47.5% but the contrast group was 25.4 % （P 〈 0.01）. （3） 1-year tumour control rate in the experiment group was 62.3%, more than that in the contrast group 44.1% （P 〈 0.05）. 1-year、2-year survival rate of the experiment group was 72.1%、59%, the Contrast group 54.2%、40.7% and the westen medicine group 51.7%、41.7% （P 〈 0.05）. 1-year tumor local control rate and 1-、2-year survival rate in the group 3 showed especially difference （P 〈 0.05）. （4） The side effects： The irradiated esophagitis rate in the experiment group was 41%, the contract group was 69.5 %, and the westen medicine group 63.3% （P 〈 0.01, P 〈 0.05）. The WBC less than 4.0×10^9/L in the experiment group was 24.6%, the contrast group 52.5% （P 〈 0.01）, and the westen medicine group 48.3% （P 〈 0.01）. The function of the liver and the kidney showed not difference before and after the radiotherapy （P 〉 0.05）. Conclusion： The curative effect is obvio

关 键 词：自拟中药方剂 食管癌 放射治疗 骨髓抑制 

分 类 号：R735.1[医药卫生—肿瘤]